FLT3 and acute myeloid leukemia: The most advanced of our compounds is an Fc-optimized mAb, which targets FMS-like tyrosine kinase 3 (FLT3) expressed on the cell surface of leukemic cells in the vast majority of patients with acute myeloid leukemia (AML).